X

Trial Profile

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab govitecan (Primary) ; Docetaxel; Paclitaxel; Vinflunine
Indications Urogenital cancer
Focus Registrational; Therapeutic Use
Acronyms TROPiCS-04
Sponsors Gilead Sciences; Immunomedics

Most Recent Events

30 May 2024 According to a Gilead Sciences Media Release, data from this study will be presented at an upcoming medical meeting.
30 May 2024 Primary endpoint (Overall Survival (OS)) has not been met, according to a Gilead Sciences Media Release.
30 May 2024 Results presented in a Gilead Sciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com